FFC#26/2014

Impaired secretory IgA and mucosal immunity in cystic fibrosis: contribution to lung pathology and impaired defence against bacterial infection, and role of CFTR-related epithelial changes in the regulation of the receptor-mediated IgA transcytosis

AREA 4 Lung inflammation

FFC#26/2014

Impaired secretory IgA and mucosal immunity in cystic fibrosis: contribution to lung pathology and impaired defence against bacterial infection, and role of CFTR-related epithelial changes in the regulation of the receptor-mediated IgA transcytosis
€ 0 still needed
0%
€ 48.000 goal

pRINCIPAL INVESTIGATOR

Charles Pilette (Université Catholique de Louvain, Brussels)

Partner

Virginia De Rose (Dip. di Scienze Biologiche e Cliniche, Università di Torino)

Researchers

5

Category

AREA 4 Lung inflammation

Duration

2 years

Goal

€ 48.000

Funds raised

€ 48.000

Objectives

This project aimed to investigate whether the production of secretory IgA (S-IgA) is impaired in the CF lung, through which mechanisms, and whether this defect contributes to the pathogenesis of CF disease by impairing immunoprotection against respiratory pathogens such as Pseudomonas aeruginosa. The hypothesis was that pIgR (bronco-epithelial receptor poli Ig) expression is reduced in CF epithelia, as a result of CFTR-related epithelial changes and epithelial inflammatory damage; this might result in profound defects in the pIgR IgA system, leading to impaired IgA-mediated immune exclusion of respiratory pathogens, and thereby favouring chronic bacterial colonization and infections in CF. New data might pave the avenue toward improving lung mucosal defence against bacteria in patients with cystic fibrosis.

WHO ADOPTED THE PROJECT

Delegazione FFC di Lecce

€ 15.000

Delegazione FFC di Alba Cuneo

€ 20.000

Delegazione FFC di Sondrio – Valchiavenna

€ 13.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches